STX: Shield Therapeutics plc - Summary | Jitta

Shield Therapeutics plc

LON:STX

Price
£0.07
Loss Chance
54.1%
2.54JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
464 / 851
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (57)
Recent Business Performance (64)
Financial Strength (33)
Return to Shareholders (20)
Competitive Advantage (54)
Jitta Signs
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2025
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.54
100.00%
3.76
110.86%
3.12
135.95%
Pharmaceuticals
1.36
100.00%
4.89
20.44%
6.32
116.24%
COMPANY DESCRIPTION
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.